Clinical Trial

Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments

Study acronym: CIBERbBECHO
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the superiority of esmolol echocardiography over conventional echocardiography in the diagnosis of subclinical myocardial involvement associated with diabetes mellitus 2, cirrhosis and antineoplastic treatments.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-03-03; most recent amendment 2024-09-30.
Status change: Not Yet Recruiting → Recruiting 2023-04-27
Trial Details
NCT Number NCT05769868
Lead Sponsor Consorcio Centro de Investigación Biomédica en Red (CIBER)
Collaborators: Instituto de Salud Carlos III
Conditions Cirrhosis, Diabetes Mellitus, Oncologic Disorders
Enrollment 1,000 participants
Start Date 2023-04-18
Primary Completion 2027-03 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2024-10-01